image description

Tag: Target Identification in Lupus

Skin Molecules Promote Cutaneous Lupus

June 24, 2019 Patients with cutaneous lupus develop rashes because immune cells move into the skin and cause inflammation. With a Target Identification in Lupus (TIL) grant from the Lupus Research Alliance, Dr. Jillian Richmond of the University of Massachusetts Medical School and colleagues found what lures the immune cells into the skin of people […] Read More

New Study Partly Funded by LRA Reveals Novel Lupus Drug Targets

NEW YORK, NY – May 29. Researchers partly funded by the Lupus Research Alliance (LRA) have found possible new targets for drugs to treat lupus after snapping the first close-up of a molecule that promotes inflammation. The molecule that Target Identification in Lupus (TIL) grant recipient Dr. Roger Greenberg at University of Pennsylvania and Dr. […] Read More

Celebrate Clinical Trials Day May 20!

May 20, 2019 It’s Clinical Trials Day when the Lupus Research Alliance recognizes all the people we support who advance clinical research – scientists who identify and develop potential ways to diagnose, monitor and treat lupus,  researchers who design and conduct the studies to test these methods, and the volunteers who take part in the […] Read More

LRA Grant Leads to New Drug Candidate RSLV-132

May 10, 2019 Grant support from the Lupus Research Alliance (then ALR) supported early work that led to a potential new drug, RSLV-132. In lupus, antibodies can target DNA’s chemical cousin RNA, which performs a variety of jobs in cells. When these antibodies encounter an RNA molecule, they attach to it, forming clusters that can […] Read More

The Numbers Add Up to 20 Years of Extraordinary Progress

May 1, 2019 The Lupus Research Alliance is honored to serve the lupus community as the global leader in lupus research, both in the resources we deploy and the results we deliver.  Collectively we have invested more than $200 million in over 500 grants selected by a multi-level peer review process led by world-class luminaries […] Read More

LRA-funded Research Backs New Lupus Nephritis Clinical Trial

February 28, 2019 The biotechnology company Equillium Inc. just announced plans for a Phase 1 study to test the investigational monoclonal antibody EQ001 as a potential treatment for lupus nephritis (LN) that has not responded to existing treatment. The basis for this study is in part due to work conducted by Dr. Chandra Mohan that […] Read More

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […] Read More

Bold Initiatives … Tremendous Strides Breaking Through on Lupus Research

In 2018 the Lupus Research Alliance has taken daring chances, pursued bold initiatives, and made tremendous strides! We truly are breaking through on many pioneering fronts of lupus research — thanks to the unwavering generosity of donors at all levels of support. Throughout the year, the brilliant scientists we brought to the table ushered in […] Read More

Potential New Lupus Treatment Outperforms Hydroxychloroquine in Animal Study

November 28, 2018 Anti-malaria drugs such as hydroxychloroquine are common treatments for arthritis and heat rash in patients with lupus. A new study by Target Identification in Lupus grantee Keith Elkon, MD, of the University of Washington, Seattle, and colleagues suggests that a new drug they designed works better than the commonly prescribed hydroxychloroquine in […] Read More

LRA Research Director Presents at ACR Roundtable

October 22, 2018 Our Research Director, Dr. Teodora Staeva, presented at the “Meet the Funders: NIH & Foundation Roundtable Grant Discussion” October 22 at the American College of Rheumatology (ACR) annual meeting. Dr. Staeva spoke about the Lupus Research Alliance many grant programs available to scientists including the  Target Identification in Lupus, Novel Research Grant, Analysis of Lupus […] Read More

Potential Treatment for Sun Damage Discovered with LRA Funding

August 16, 2018 Exposure to the sun is hard on everyone’s skin, causing cells to die. But skin cells are much more vulnerable in people with lupus.  That reaction is called photosensitivity. A team of scientists led by Theresa Lu, MD, PhD, at Hospital for Special Surgery (HSS) in New York may have discovered why. […] Read More